C. Chiang

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.

A. Saunders, C. Dyck, C. V. van Dyck, 2011, Current Alzheimer research.

Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

L. Schneider, D. Bennett, Y. Stern, 2021, The Journal of Prevention of Alzheimer's Disease.

A pharmacogenetics-supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease

A. Roses, K. Welsh-Bohmer, A. Saunders, 2013, Alzheimer's & Dementia.

A pharmacogenetic-supported clinical trial to delay onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD)

A. Roses, K. Welsh-Bohmer, S. Brannan, 2012, Alzheimer's & Dementia.

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Jennifer G. Robinson, Alex A. Knopman, D. Rujescu, 2021, The Lancet Neurology.

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial

L. Schneider, C. Lyketsos, A. Monsch, 2019, Alzheimer's & dementia.

TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM

K. Welsh-Bohmer, A. Saunders, J. Burke, 2019, Alzheimer's & Dementia.